We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
-0.18%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$383M
AUM Growth
+$150M
Cap. Flow
+$155M
Cap. Flow %
40.41%
Top 10 Hldgs %
48.06%
Holding
163
New
56
Increased
35
Reduced
10
Closed
61

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.5M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.45M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$7.89M
5
ARGX icon
argenx
ARGX
+$7.32M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$9.05M
2
ABBV icon
AbbVie
ABBV
+$8.88M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.68M
4
BPMC
Blueprint Medicines
BPMC
+$5.6M
5
AZN icon
AstraZeneca
AZN
+$3.93M

Sector Composition

Rank Sector Weight
1 Healthcare 32.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
101
PUT
Jazz Pharmaceuticals
JAZZ
$15.8B
$12.4K ﹤0.01%
+100
New +$13K
VTGN icon
102
CALL
VistaGen Therapeutics
VTGN
$10.1M
$500 ﹤0.01%
200
– –
ABBV icon
103
AbbVie
ABBV
$433B
– –
-50,000
Closed -$8.88M
ABBV icon
104
PUT
AbbVie
ABBV
$433B
– –
-50,000
Closed -$8.88M
ACLX
105
DELISTED
Arcellx
ACLX
– –
-10,100
Closed -$775K
ACLX
106
PUT
DELISTED
Arcellx
ACLX
– –
-100,000
Closed -$7.67M
ALXO icon
107
CALL
ALX Oncology
ALXO
$260M
– –
-38,900
Closed -$65K
ALXO icon
108
ALX Oncology
ALXO
$260M
– –
-197,680
Closed -$330K
APLS
109
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-100,000
Closed -$3.19M
APVO icon
110
Aptevo Therapeutics
APVO
$4.92M
– –
-11
Closed -$17.5K
ARVN icon
111
PUT
Arvinas
ARVN
$520M
– –
-2,300
Closed -$44.1K
JBIO
112
PUT
Jade Biosciences
JBIO
$1.17B
– –
-5,474
Closed -$508K
AZN icon
113
AstraZeneca
AZN
$245B
– –
-15,000
Closed -$3.93M
BHVN icon
114
CALL
Biohaven
BHVN
$2.01B
– –
-100,000
Closed -$3.73M
BMY icon
115
Bristol-Myers Squibb
BMY
$134B
– –
-160,000
Closed -$9.05M
BNTX icon
116
BioNTech
BNTX
$23.3B
– –
-8,767
Closed -$999K
BPMC
117
DELISTED
Blueprint Medicines
BPMC
– –
-64,193
Closed -$5.6M
CADL icon
118
PUT
Candel Therapeutics
CADL
$738M
– –
-32,900
Closed -$286K
CAPR icon
119
PUT
Capricor Therapeutics
CAPR
$243M
– –
-58,700
Closed -$810K
CCCC icon
120
CALL
C4 Therapeutics
CCCC
$387M
– –
-80,100
Closed -$288K
CLDX icon
121
CALL
Celldex Therapeutics
CLDX
$2.96B
– –
-100,000
Closed -$2.53M
CRNX icon
122
Crinetics Pharmaceuticals
CRNX
$8.89B
– –
-25,900
Closed -$1.32M
DNLI icon
123
Denali Therapeutics
DNLI
$3.67B
– –
-60,000
Closed -$1.22M
EOLS icon
124
Evolus
EOLS
$398M
– –
-97,423
Closed -$1.27M
ERAS icon
125
Erasca
ERAS
$6.19B
– –
-156,973
Closed -$394K
3 4
5
6 7

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Diadema Partners held 163 positions worth $383M, up 64% from $233M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Diadema Partners deployed $155M of net new capital in Q1 2025, opening 56 new positions and adding to 35 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $2.42M trimmed.

  • Diadema Partners's largest Q1 2025 buy was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.
  • Diadema Partners added most to Jazz Pharmaceuticals in Q1 2025, an estimated $9.45M increase.
  • Diadema Partners's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $2.42M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q1 2025, selling an estimated $9.05M.
  • Diadema Partners's ten largest holdings make up 48% of its $383M portfolio in Q1 2025.
  • Diadema Partners opened 56 new positions and closed 61 in Q1 2025.
  • Diadema Partners's portfolio value rose 64% quarter-over-quarter to $383M.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.